Rejoni, a clinical-stage company focused on uterine health, has closed $25 million in financing from investors including ClavystBio, Amed Ventures, Ascension Ventures, Catalyst Health Ventures, Delos Capital, FemHealth Ventures, Iyengar Capital, and Sparta Group.
The funding will prepare for the commercial launch of the Juveena Hydrogel System, Rejoni’s first product, which is designed to support endometrial healing within the uterine cavity following intrauterine surgery. The system uses a proprietary transcervical catheter to place a soft, temporary hydrogel spacer inside the uterine cavity during the healing process, aiming to reduce the incidence and severity of intrauterine adhesions (IUAs) – a leading complication of intrauterine surgery that can cause pain, menstrual irregularities, and infertility.
Proceeds will go toward scaling manufacturing and supply operations, market access, physician and patient engagement, and commercial readiness ahead of anticipated FDA approval.
“Uterine health has been underserved for too long, and this financing puts us in a position to change that,” said CEO John Nealon. “We are building the infrastructure, commercial readiness, market access, and physician engagement to ensure we can move quickly when Juveena is approved.”
Rejoni was founded in 2020 by serial entrepreneur Amar Sawhney, who previously founded Confluent Surgical, Ocular Therapeutix, and Augmenix. Juveena is pending FDA approval and is not yet available for sale.
